DOSE is an AI-powered ADHD skills support platform growing at 20%+ month-over-month, bootstrapped entirely through coaching revenue, with zero paid marketing.
Raising $1.2 Million on $7.5M Cap SAFE
In April 2026, Cerebral, a $4.8B mental health platform, made only its second-ever acquisition — choosing an ADHD digital app. This confirms that large clinical platforms are actively acquiring AI-powered ADHD tools to complete their care continuum. DOSE is purpose-built for exactly this acquirer profile.
Rejection Sensitivity Dysphoria (RSD) is widely reported among adults with ADHD, with estimates suggesting it affects a significant majority of the population.3 Despite this, dedicated self-guided support tools for RSD experiences have been virtually nonexistent until DOSE.
While competitors focus on productivity and psychoeducation, DOSE addresses the in-the-moment support gap — skills-based tools that work when ADHD brains are emotionally overwhelmed, not just when calm. This is the gap Cerebral moved to fill when they acquired Inflow. DOSE goes further.
We are not building a better productivity app. We are creating an entirely new category: skills-based cognitive support for neurodivergent minds at the moment they need it most.
DOSE is actively building clinical governance infrastructure to ensure the platform is safe, evidence-informed, and defensible at scale.
Active search underway for an ICF-credentialed psychologist or psychiatrist with ADHD specialization to serve as CCO and anchor our clinical advisory board.
90-day roadmap underway including theoretical mapping of SPARK and WAVE to ACT and DBT frameworks, RSD Meter cross-referencing with A-RSQ, and ACOS-SR outcome tracking.
Crisis escalation protocols, AI guardrails, universal safety disclaimers, and adverse event review processes being implemented across all platform surfaces.
Actively positioning DOSE within the FDA General Wellness Non-Device lane with CBT-informed and DBT-informed language, HIPAA-aware data practices, and FTC-compliant claims.
Pursuing academic research partnerships for pilot studies, outcome tracking, and peer-reviewed publication of DOSE efficacy data.
DOSE is explicitly positioned as adjunctive skills support, not therapy, diagnosis, or emergency care. All platform language, terms, and disclaimers reflect this clearly.
Adult ADHD diagnoses up 30% in five years.1 Social destigmatization creating unprecedented market expansion.
Cerebral acquired Inflow in April 2026. UHS acquired Talkspace in March 2026. Strategic buyers are actively consolidating the space.
$5.6B invested in digital mental health in 2023.4 Digital therapeutics gaining FDA pathways and insurance coverage.
Therapy waitlists average 3 to 6 months nationally. Demand for between-session and in-the-moment support tools has never been higher.
Neurodiversity workplace spending growing 40% annually. Employers actively seeking ADHD-specific support tools for their workforce.
AI-assisted development tools allow DOSE to ship features in days that previously took weeks.
Steev Hodgson brings a combination rarely seen in mental health technology:
✓ Clinical Depth: ICF-credentialed ADHD coach with 1,300+ completed coaching sessions
✓ Lived Experience: Late-in-life ADHD diagnosis at age 48, authentic understanding of the adult ADHD journey
✓ Technical Execution: Self-taught developer who built the original DOSE platform from scratch in Flutter/Dart
✓ Enterprise Sales: 20+ years in enterprise technology sales at Red Hat, New Relic, LaunchDarkly, and CloudBees, including deals up to $3M
✓ Community Credibility: 20+ national podcast appearances, speaker at International ADHD Conference and UC Berkeley NOW Conference
This clinical expertise combined with technical capability and enterprise sales background creates a defensible competitive moat that is difficult to replicate.
DOSE provides self-guided educational and coping-skills tools for ADHD-related emotional overwhelm, rejection sensitivity experiences, and executive function challenges. DOSE is not therapy, psychological treatment, medical care, diagnosis, medication advice, or emergency response. DOSE is not an FDA-cleared or FDA-approved medical device. Clinical efficacy has not yet been established through formal peer-reviewed studies. The platform is informed by evidence-based frameworks including CBT and DBT principles and the founder's 1,300+ ADHD coaching sessions.
Traction metrics including conversion rate, retention, and MRR reflect internal tracking as of April 2026. Market size figures are sourced from published research cited in the footnotes below. RSD prevalence estimates are drawn from clinical literature; RSD is not currently a standalone DSM-5-TR diagnosis. All forward-looking statements including milestone projections are aspirational and subject to change. This page does not constitute a securities offering. Investment inquiries are subject to applicable securities laws.
For urgent mental health support: Call or text 988 — Suicide and Crisis Lifeline. Call 911 for emergencies.
Interested in learning more about this investment opportunity? Review our materials and reach out directly.
Currently in conversations with strategic partners. Pre-seed round open.